Exenatide Affects Circulating Cardiovascular Risk Biomarkers Independently of Changes in Body Composition

2010155 citationsJournal Articlehybrid Open Access

Authors

Mathijs C. Bunck · Amsterdam UMC Location VUmc

Michaëla Diamant · Amsterdam UMC Location VUmc

Björn Eliasson · Sahlgrenska University Hospital

A. H. Corner · Helsinki University Hospital

Rimma M. Shaginian · Eli Lilly (Netherlands)

Robert J. Heine · Eli Lilly (United States)

Marja‐Riitta Taskinen

Abstract

Exenatide treatment for 1 year reduced body fat mass and improved the profile of circulating biomarkers of cardiovascular risk. No significant changes were seen with insulin glargine except a trend for reduced endothelin-1 levels.

Topics & Keywords

Diabetes Treatment and Management Metabolism, Diabetes, and Cancer Pancreatic function and diabetes

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Diabetes Care

Volume 33, Issue 8, pp. 1734-1737

DOI: 10.2337/dc09-2361

Field-Weighted Citation Impact: 9.42